Factors associated with the success of trial without catheter in acute urinary retention due to benign prostatic hyperplasia

IF 0.8 Q4 UROLOGY & NEPHROLOGY Urological Science Pub Date : 2021-03-01 DOI:10.4103/UROS.UROS_130_20
Dinh Thi Phuong Hoai, Luu Lam Thang Tai, Tran Huu Loc, Muawia Fadlelmola Mohamed, Ali Ahmed, Nguyen Huy, L. Khanh
{"title":"Factors associated with the success of trial without catheter in acute urinary retention due to benign prostatic hyperplasia","authors":"Dinh Thi Phuong Hoai, Luu Lam Thang Tai, Tran Huu Loc, Muawia Fadlelmola Mohamed, Ali Ahmed, Nguyen Huy, L. Khanh","doi":"10.4103/UROS.UROS_130_20","DOIUrl":null,"url":null,"abstract":"Purpose: This study aims to evaluate the parameters that can predict the success or failure of trial without catheter (TWOC) for acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH). Materials and Methods: A prospective cohort study was conducted to include 73 medically treated patients with AUR due to BPH. All patients underwent catheterization and were started on alfuzosin (10 mg/day), followed by TWOC. Age, international prostate symptom score (IPSS), quality of life, prostate volume, and urine volume after catheterization were analyzed. Results: Patients' mean age was 74.23 ± 9.63 years; the first successful and failed TWOC was reported in 47 (64.4%) and 26 patients (35.6%), respectively. On the one hand, 89.4% of the patients continued medical treatment with alfuzosin (10 mg/day) in the first successful TWOC group. On the other hand, 30.8% showed the second successful TWOC and continued medical treatment in the first TWOC failure group. The uni- and multivariable analyses in this study showed that severe lower urinary tract symptoms (IPSS ≥20 points), prostatic pain during digital rectal examination (DRE), high urine volume after catheterization (≥950 mL), and high blood urea (≥4.55 mmol/L) were the predictive factors of TWOC failure. Conclusion: Severe lower urinary tract symptoms, prostatic pain during DRE, large urine volume after catheterization, and high blood urea are the predictive factors for TWOC failure in AUR due to BPH.","PeriodicalId":23449,"journal":{"name":"Urological Science","volume":"32 1","pages":"71 - 76"},"PeriodicalIF":0.8000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urological Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/UROS.UROS_130_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study aims to evaluate the parameters that can predict the success or failure of trial without catheter (TWOC) for acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH). Materials and Methods: A prospective cohort study was conducted to include 73 medically treated patients with AUR due to BPH. All patients underwent catheterization and were started on alfuzosin (10 mg/day), followed by TWOC. Age, international prostate symptom score (IPSS), quality of life, prostate volume, and urine volume after catheterization were analyzed. Results: Patients' mean age was 74.23 ± 9.63 years; the first successful and failed TWOC was reported in 47 (64.4%) and 26 patients (35.6%), respectively. On the one hand, 89.4% of the patients continued medical treatment with alfuzosin (10 mg/day) in the first successful TWOC group. On the other hand, 30.8% showed the second successful TWOC and continued medical treatment in the first TWOC failure group. The uni- and multivariable analyses in this study showed that severe lower urinary tract symptoms (IPSS ≥20 points), prostatic pain during digital rectal examination (DRE), high urine volume after catheterization (≥950 mL), and high blood urea (≥4.55 mmol/L) were the predictive factors of TWOC failure. Conclusion: Severe lower urinary tract symptoms, prostatic pain during DRE, large urine volume after catheterization, and high blood urea are the predictive factors for TWOC failure in AUR due to BPH.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
无导管治疗良性前列腺增生急性尿潴留试验成功的相关因素
目的:本研究旨在评估可预测无导管(TWOC)治疗良性前列腺增生(BPH)引起的急性尿潴留(AUR)试验成败的参数。材料和方法:进行了一项前瞻性队列研究,包括73名接受药物治疗的BPH引起的AUR患者。所有患者均接受导管插入术,开始服用阿呋唑嗪(10 mg/天),然后服用TWOC。分析年龄、国际前列腺症状评分(IPSS)、生活质量、前列腺容量和导尿后尿量。结果:患者平均年龄74.23±9.63岁;首次成功和失败的TWOC分别为47例(64.4%)和26例(35.6%)。一方面,在第一个成功的TWOC组中,89.4%的患者继续接受阿呋唑嗪(10mg/天)的药物治疗。另一方面,30.8%的患者第二次TWOC成功,并在第一次TWOC失败组中继续接受药物治疗。本研究中的单因素和多因素分析表明,严重的下尿路症状(IPSS≥20分)、直肠指检(DRE)中的前列腺疼痛、导管插入术后的高尿量(≥950 mL)和高血尿素(≥4.55 mmol/L)是TWOC失败的预测因素。结论:严重的下尿路症状、DRE过程中的前列腺疼痛、导尿后的大尿量和高血尿素是BPH引起的AUR TWOC失败的预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Urological Science
Urological Science UROLOGY & NEPHROLOGY-
CiteScore
1.20
自引率
0.00%
发文量
26
审稿时长
6 weeks
期刊最新文献
Clinical guidelines of patient-centered bladder management of neurogenic lower urinary tract dysfunction due to chronic spinal cord injury – Part 3: Surgical treatment in chronic spinal cord injured patients Collecting duct carcinoma of the kidney: Clinicopathological profile and outcomes “Rule of Five” in Ureteral Dilatation and its Role in Ureteral Access Sheath Placement during Retrograde Intrarenal Surgery Testicular tumor patients presented with scrotal violation-nonstandard surgical approach and its survival rate Level of scientific evidence underlying recommendations arising from the functional urology guidelines
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1